Provided by Tiger Trade Technology Pte. Ltd.

ProKidney Corp.

2.22
-0.0200-0.89%
Volume:569.27K
Turnover:1.27M
Market Cap:667.85M
PE:-4.09
High:2.30
Open:2.26
Low:2.15
Close:2.24
52wk High:7.13
52wk Low:0.4603
Shares:300.83M
Float Shares:274.16M
Volume Ratio:1.57
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5433
EPS(LYR):-0.6249
ROE:-41.81%
ROA:-25.85%
PB:-0.66
PE(LYR):-3.55

Loading ...

U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart

Reuters
·
Feb 11

ProKidney Corp : Jefferies Assumes Coverage With Buy Rating; Target Price $4.5 VS $6

THOMSON REUTERS
·
Feb 11

BRIEF-Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027

Reuters
·
Feb 03

ProKidney Corp - Topline Data Readout of Surrogate Endpoint Expected Q2 2027 - SEC Filing

THOMSON REUTERS
·
Feb 03

ProKidney Corp - Updates Phase 3 Study Enrollment to 470 Subjects - SEC Filing

THOMSON REUTERS
·
Feb 03

3 Penny Stocks With Market Caps Under $700M

Simply Wall St.
·
Jan 08

HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target

MT Newswires Live
·
Dec 16, 2025

ProKidney Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 16, 2025

ProKidney Corp. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Dec 16, 2025

ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares

Reuters
·
Nov 15, 2025

ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate

Benzinga
·
Nov 11, 2025

ProKidney reports Q3 2025 results and updates on Phase 3 CKD therapy trial

Reuters
·
Nov 11, 2025

ProKidney: Q3 Net Loss per Share Attributable to Class a Stock $0.12

THOMSON REUTERS
·
Nov 11, 2025

Press Release: ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Dow Jones
·
Nov 11, 2025

Prokidney Corp expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

ProKidney Announces Phase 3 Trial Progress for Rilparencel in Advanced CKD and Diabetes

Reuters
·
Nov 07, 2025

ProKidney Presents Full Results From the Phase 2 Regen-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

THOMSON REUTERS
·
Nov 07, 2025

ProKidney Corp. to Join Guggenheim Healthcare Innovation Conference

Reuters
·
Oct 29, 2025

BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing

Reuters
·
Oct 18, 2025

ProKidney Corp - to Sell Greensboro Property for $19.1 Mln - SEC Filing

THOMSON REUTERS
·
Oct 18, 2025